Clinical aspects of Alzheimer’s disease

2001 ◽  
Vol 13 (3) ◽  
pp. 221-230 ◽  
Author(s):  
A. Bianchetti ◽  
M. Trabucchi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Aspects

Rationale for combination therapy with galantamine and memantine in alzheimer’s disease: the efficacy of treatment of addition

2011 ◽  
Vol 26 (S2) ◽  
pp. 507-507
Author(s):  
J. Zarra
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Adverse Events ◽  
Well Being ◽  
Disease Assessment ◽  
Clinical Aspects ◽  
Neurocognitive Disorder ◽  
Clinical Dementia Rating ◽  
Open Label ◽  
Behavioural Symptoms

ObjectiveThe efficacy, safety, and tolerability of nootropic cholinergic agent: GALANTAMINE (with a dual mechanism of action on the cholinergic a system) and moderate affinity NMDA- receptor antagonist: MEMANTINE, were assessed taking into account the profile of patients with neurocognitive disorder: Alzheimer's disease, from the clinical aspects and the different classifications.MethodsThe experience included 428 patients who were enrolled in a prospective, observational, multicenter, and open-label study to receive 16 mg/day of galantamine and 30 mg/day of memantine for 12 months of treatment of addition.ResultsThe therapeutic response was measured using the Mini Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Alzheimer's Disease Assessment Scale (ADAS-GOG), Functional Activities Questionnaire(FAQ) the Clinical Global Impression Scale (CGI) and the UKU scale of adverse effectstaking into account the efficacy, safety and adverse events of the treatment.The final results of the study showed that galantamine with addition memantine improves cognition, behavioural symptoms, and the general well-being of patients with cognitive impairment: Alzheimer's disease. The incidence of adverse events was not significant and a very good profile of tolerability and safety was observed.ConclusionAt the conclusion of this session, the participant should be able to demonstrate with use the association memantine - galatamine in neurocognitive disorder: Alzheimer's disease, improve cognition, behavioural symptoms, and the general state recognized as neurocognitive disorder.

Clinical Aspects of ‘Senile Dementia of the Tangle Type’ – A Subset of Dementia in the Senium Separable from Late-Onset Alzheimer’s Disease

1998 ◽  
Vol 10 (1) ◽  
pp. 6-11 ◽  
Author(s):  
Kenji Ikeda ◽  
Haruhiko Akiyama ◽  
Tetsuaki Arai ◽  
Tatsuro Oda ◽  
Masanori Kato ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Late Onset ◽  
Senile Dementia ◽  
Type A ◽  
Clinical Aspects ◽  
Senile Dementia Of The

Selective Serotonin Reuptake Inhibitors and Trazodone for Treatment of Depression, Psychosis, and Behavioral Symptoms in Patients With Dementia

2000 ◽  
Vol 12 (S1) ◽  
pp. 245-251 ◽  
Author(s):  
David L. Sultzer
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Adverse Effects ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Behavioral Symptoms ◽  
Selective Serotonin ◽  
Clinical Aspects ◽  
Treatment Of Depression

Depression, psychosis, agitation, and aggression are fundamental clinical aspects of Alzheimer's disease (AD) and other dementia syndromes. Although behavioral, environmental, and pharmacologic interventions often help ameliorate these symptoms, the efficacy of specific interventions is uncertain, and adverse effects of medications are common.

Sign in / Sign up

Export Citation Format

Share Document